Table 2.
Comprehensive histologic assessment of paraffin-embedded samples
| Case | Presentation (interval) | Tumor | Location | Type | Subtype | Cytology or stroma | Histologic Comparison | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Acinar | Papillary | BAC | Solid | Micro-papillary | |||||||
| 1 | synchronous | A | LLL | ADC | 0% | 60% | 40% | 0% | 0% | different | |
| B | RLL | ADC | 10% | 80% | 10% | 0% | 0% | lymphoid hyperplasia | |||
| 2 | synchronous | A | LLL | ADC | 0% | 0% | 100% | 0% | 0% | different | |
| B | RUL | ADC | 20% | 0% | 80% | 0% | 0% | ||||
| 3 | synchronous | A | RUL | ADC | 20% | 20% | 0% | 0% | 60% | different | |
| B | LUL | ADC | 10% | 70% | 0% | 0% | 20% | ||||
| 4 | synchronous | A | RLL | ADC | 10% | 50% | 30% | 0% | 10% | different | |
| B | LUL | ADC | 20% | 40% | 0% | 10% | 30% | ||||
| 5 | synchronous | A | LLL | ADC | 60% | 40% | 0% | 0% | 0% | different* | |
| B | LUL | LCNEC | n/a | n/a | n/a | n/a | n/a | different# | |||
| C | RUL | ADC | 20% | 0% | 0% | 80% | 0% | different ^ | |||
| 6 | synchronous | A | RUL | ADC | 10% | 50% | 30% | 0% | 10% | signet ring | similar |
| B | LLL | ADC | 30% | 50% | 10% | 0% | 10% | signet ring | |||
| 7 | metachronous (14.1 months) | A | LLL | ADC | 10% | 80% | 10% | 0% | 0% | mucinous | similar |
| B | RML | ADC | 0% | 100% | 0% | 0% | 0% | mucinous | |||
| 8 | metachronous (51.1 months) | A | LUL | ADC | 10% | 0% | 0% | 90% | 0% | different | |
| B | RUL | LCNEC | n/a | n/a | n/a | n/a | n/a | ||||
| 9 | metachronous (41.2 months) | A | RLL | ADC | 10% | 80% | 0% | 0% | 10% | similar | |
| B | RUL | ADC | 10% | 80% | 0% | 0% | 10% | ||||
| 10 | metachronous (25.1 months) | A | LUL | SCC | n/a | n/a | n/a | n/a | n/a | desmoplastic stroma necrosis |
different |
| B | RLL | SCC | n/a | n/a | n/a | n/a | n/a | inflammatory stroma | |||
| 11 | metachronous (42.7 months) | A | LUL | ADC | 10% | 0% | 0% | 90% | 0% | different | |
| B | RLL | ADC | 20% | 30% | 0% | 0% | 50% | ||||
| 12 | metachronous (23.0 months) | A | RUL | ADC | 20% | 70% | 0% | 10% | 0% | clear cells | different |
| B | LUL | ADC | 60% | 40% | 0% | 0% | 10% | ||||
| 13 | metachronous (18.9 months) | A | RLL | ADC | 0% | 50% | 40% | 0% | 10% | “miliary-like” extension | similar |
| B | RUL | ADC | 20% | 80% | 0% | 0% | 0% | “miliary-like” extension | |||
| 14 | metachronous (18.6 months) | A | RUL | ADC | 90% | 0% | 10% | 0% | 0% | different | |
| B | LUL | ADC | 80% | 10% | 0% | 10% | 0% | ||||
| 15 | metachronous (50.2 months) | A | LUL | SCC | n/a | n/a | n/a | n/a | n/a | different | |
| B | RUL | SCC | n/a | n/a | n/a | n/a | n/a | necrosis | |||
| 16 | metachronous (53.6 months) | A | LLL | SCC | n/a | n/a | n/a | n/a | n/a | different | |
| B | LUL | ADC | 10% | 90% | 0% | 0% | 0% | ||||
| 17 | metachronous (33.3 months) | A | LUL | SCC | n/a | n/a | n/a | n/a | 0% | different | |
| B | RUL | ADC | 0% | 60% | 40% | 0% | 0% | clear cells | |||
| 18 | metachronous (72.2 months) | A | LUL | ADC | 20% | 20% | 60% | 0% | 0% | mucinous | different |
| B | RLL | ADC | 30% | 50% | 0% | 0% | 0% | fetal (20%) | |||
| 19 | metachronous (13.5 months) | A | LLL | SCC | n/a | n/a | n/a | n/a | n/a | sarcomatoid/basaloid | similar |
| B | LLL | SCC | n/a | n/a | n/a | n/a | n/a | sarcomatoid/basaloid | |||
| 20 | metachronous (6.6 months*) (11.5 months#) (18.1 months^) | A | LLL | ADC | 0% | 30% | 0% | 60% | 10% | clear cells | similar* |
| B | LUL | ADC | 30% | 20% | 0% | 50% | 0% | clear cells | similar# | ||
| C | LUL | ADC | 10% | 10% | 0% | 80% | 0% | clear cells | similar ^ | ||
ADC: adenocarcinoma; SCC: squamous cell carcinoma; LCNEC: large-cell neuroendocrine carcinoma; BAC: bronchiolo-alveolar carcinoma; n/a: not applicable;
*
tumor A vs. tumor B;
#
tumor B vs. tumor C;
^
tumor A vs. tumor C